![Robert A. Hamm](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Robert A. Hamm
Keine laufenden Positionen mehr
Profil
Mr. Robert A.
Hamm is Chief Operating Officer at Biogen Idec New Ventures, Inc. and Chief Operating Officer & Executive Vice President at Biogen Idec, Inc. He was previously employed as Senior Vice President-Immunology Business Unit by Biogen, Inc. He also served on the board at Inhibitex, Inc. and Syntex Laboratories, Inc.
Mr. Hamm received his undergraduate degree from St. Bonaventure University and a graduate degree from Central Michigan University.
Ehemalige bekannte Positionen von Robert A. Hamm
Unternehmen | Position | Ende |
---|---|---|
BIOGEN INC. | Geschäftsführer | 31.12.2010 |
Inhibitex LLC
![]() Inhibitex LLC Pharmaceuticals: MajorHealth Technology Inhibitex, Inc. operates as an clinical-stage biopharmaceutical company. The firm develops differentiated anti-infective products to prevent or treat serious infections. Its research and development efforts are currently focused on oral, small molecule compounds to treat viral infections, and in particular, chronic infections caused by HCV and herpes zoster. The company was founded by Joseph M. Patti in May 1994 and is headquartered in Alpharetta, GA. | Direktor/Vorstandsmitglied | 01.04.2009 |
Biogen MA, Inc.
![]() Biogen MA, Inc. BiotechnologyHealth Technology Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01.11.2003 |
Syntex Laboratories, Inc. | Corporate Officer/Principal | 01.04.1994 |
Biogen Idec New Ventures, Inc.
![]() Biogen Idec New Ventures, Inc. Investment ManagersFinance Founded in 2004, Biogen Idec New Ventures is the corporate venture group of Biogen Idec, Inc. In 2003, Biogen and IDEC Pharmaceuticals merged to create Biogen Idec, Inc. (NASDAQ: BIIB) | Geschäftsführer | - |
Ausbildung von Robert A. Hamm
St. Bonaventure University | Undergraduate Degree |
Central Michigan University | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
BIOGEN INC. | Health Technology |
Private Unternehmen | 4 |
---|---|
Inhibitex LLC
![]() Inhibitex LLC Pharmaceuticals: MajorHealth Technology Inhibitex, Inc. operates as an clinical-stage biopharmaceutical company. The firm develops differentiated anti-infective products to prevent or treat serious infections. Its research and development efforts are currently focused on oral, small molecule compounds to treat viral infections, and in particular, chronic infections caused by HCV and herpes zoster. The company was founded by Joseph M. Patti in May 1994 and is headquartered in Alpharetta, GA. | Health Technology |
Biogen MA, Inc.
![]() Biogen MA, Inc. BiotechnologyHealth Technology Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA. | Health Technology |
Syntex Laboratories, Inc. | |
Biogen Idec New Ventures, Inc.
![]() Biogen Idec New Ventures, Inc. Investment ManagersFinance Founded in 2004, Biogen Idec New Ventures is the corporate venture group of Biogen Idec, Inc. In 2003, Biogen and IDEC Pharmaceuticals merged to create Biogen Idec, Inc. (NASDAQ: BIIB) | Finance |